Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | IDH1 | O75874 | 7/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | IL6ST | P40189 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | USP19 | O94966 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19815463 | 0.99 | PPARA (0.41) | PPARAIDH1ATMIL6STNAAA | |
| SCHEMBL19815467 | 0.99 | PPARA (0.41) | PPARAIDH1ATMIL6STNAAA | |
| SCHEMBL19815465 | 0.99 | PPARA (0.41) | PPARAIDH1ATMIL6STNAAA | |
| SCHEMBL19817224 | 0.98 | PPARA (0.42) | PPARAIDH1ATMIL6STNAAA | |
| SCHEMBL19817221 | 0.98 | PPARA (0.42) | PPARAIDH1ATMIL6STNAAA | |
| SCHEMBL19817226 | 0.98 | PPARA (0.42) | PPARAIDH1ATMIL6STNAAA | |
| SCHEMBL21197347 | 0.91 | PPARA (0.40) | PPARAIDH1ATMIL6STAGTR2 | |
| SCHEMBL21197346 | 0.91 | PPARA (0.40) | PPARAIDH1ATMIL6STAGTR2 | |
| SCHEMBL21197345 | 0.91 | PPARA (0.40) | PPARAIDH1ATMIL6STAGTR2 | |
| SCHEMBL8438051 | 0.90 | MMP2 (0.44) | PPARAIDH1ATMIL6STNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2785348-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013082388-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| US-6908911-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-06-21 | — | — | US | disclosed |
| EP-1210330-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2005-04-20 | — | — | EP | disclosed |
| WO-2000061134-A9 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2004-04-22 | — | — | WO | disclosed |
| US-6716878-B1 | BACTERICIDE, ANTIPROTOZOAL; VANCOMYCIN RESISTANT ENTEROCOCCI AND BETA-LACTAM ANTIBIOTIC-RESISTANT BACTERIA, METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; HYDROXAMIC ACID AND N-FORMYL SUBTITUTED ALKYLAMIDES | VERNALIS (OXFORD) LIMITED (GB) | 2004-04-06 | — | — | US | disclosed |
| EP-1210330-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-1169031-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001010835-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000061134-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, HAMP | PPARA 3055/4885IDH1 3240/4885ATM 3733/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | PPARA 3989/4885IDH1 1753/4885ATM 4666/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | PPARA 3854/4885IDH1 2720/4885ATM 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.